Briacell reports Bria-MEL+ milestone for melanoma vaccine program
Briacell said it reported a genetic engineering milestone for Bria-MEL+, advancing the personalized whole-cell melanoma vaccine program toward clinical development.
BCTX Briacell reported a genetic engineering milestone for Bria-MEL+, advancing its personalized whole-cell melanoma vaccine program toward clinical development.
Bria-MEL+ uses premanufactured cell lines selected via a saliva-based HLA Match, aiming to avoid patient-by-patient manufacturing.
Development work has started to support production for potential clinical use, positioning Bria-MEL+ as an expansion beyond breast cancer programs.